Skip to main content

Drug Interactions between afamitresgene autoleucel and bupivacaine / dexamethasone / epinephrine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dexAMETHasone afamitresgene autoleucel

Applies to: bupivacaine / dexamethasone / epinephrine and afamitresgene autoleucel

GENERALLY AVOID: The use of systemic corticosteroids may reduce the efficacy of afamitresgene autoleucel, an autologous T-cell immunotherapy agent. The exact mechanism by which corticosteroids exert this effect is not clearly described; however, it may involve corticosteroid-induced T lymphocyte apoptosis. The clinical trial that evaluated the efficacy of afamitresgene autoleucel excluded patients who were on systemic corticosteroids for at least 14 days prior to leukapheresis and lymphodepletion. Therefore, clinical data examining the use of systemic corticosteroids prior to or during an infusion of afamitresgene autoleucel are not available.

MANAGEMENT: The manufacturer of afamitresgene autoleucel recommends avoiding the prophylactic use of systemic corticosteroids. Consultation with institutional protocols, national guidelines, and package labeling may be helpful.

References (3)
  1. Herold MJ, McPherson KG, Reichardt HM (2024) Glucocorticoids in T cell apoptosis and function. https://link.springer.com/article/10.1007/s00018-005-5390-y
  2. Landwehr LS, Altieri B, Schreiner J, et al. (2020) "Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma." J Immunother Cancer, 8, e000469
  3. (2024) "Product Information. Tecelra (afamitresgene autoleucel)." Adaptimmune, LLC

Drug and food interactions

Moderate

EPINEPHrine food

Applies to: bupivacaine / dexamethasone / epinephrine

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer